Please let me know if you have tried this and what your experiences have been with it. You need to take quite a bit of it for it to be effective. If you haven’t tried it - perhaps try it and report back.
In this new research study:
Each person was taking: 6 grams of L-Lysine every day for four weeks
Please try it folks - and report back to the discussion forums after a few weeks of using it.
Here is where you can easily it online ($14 per pound / or 454 grams - enough for 2 + months at 6 grams a day):
http://www.iherb.com/Now-Foods-L-Lysine-Powder-1-lb-454-g/653#
or for more selection - here:
Research Information:
Schizophrenia is a serious mental disorder that currently affects about one in every 200 people. Most patients find some relief from their symptoms by treatment with antipsychotics, however they may still suffer from cognitive and negative symptoms. These include poor concentration and memory, apathy, or a reduced ability to cope in social situations. Preliminary research published in BioMed Central’s open access journal BMC Medicine shows that patients who received L-lysine alongside their normal medication found some reduction in the severity of their symptoms.
In a cross-over study, ten patients with schizophrenia were given either 6g of L-Lysine or a placebo every day for four weeks. Each of the patients had been on a stable dose of medication for the past three months and had been free from psychotic episodes for the two months before the study began. They were tested for blood levels of lysine as well as the severity of their symptoms (PANSS) and functional ability (including the Wisconsin Card Sorting and Trail Making tests) at the start, after four, and after eight weeks.
Eight of the patients responded to L-lysine treatment, as shown by an increase in blood lysine levels. For these eight there was a general trend, over most of the symptomatic and cognitive tests, for improvement due to treatment with lysine.
More details here:
Full Study Information:
L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study